EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

A multi-center, clinical analysis of IDH-mutant gliomas, WHO Grade 4: implications for prognosis and clinical trial design

Ethan A Wetzel, Amin I Nohman, Annie L Hsieh, David Reuss, Andreas W Unterberg, Ilker Y Eyüpoglu, Lingyang Hua, Gilbert Youssef, Patrick Y Wen, Daniel P Cahill, Christine Jungk, Tareq A Juratli und 1 weitere

Journal of Neuro-Oncology · 2025

DOI: 10.1007/s11060-024-04852-7 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Neuro-Oncology, 2025. Verfasst von Ethan A Wetzel und 12 weiteren Autor:innen. Beteiligte Einrichtung: Translational Neuro-Oncology Laboratory, Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Brain Neoplasms, Mutation, Cyclin-Dependent Kinase Inhibitor p16. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, NINDS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Isocitrate DehydrogenaseBrain NeoplasmsMutationCyclin-Dependent Kinase Inhibitor p16Neoplasm GradingGliomaHumansMaleFemaleMiddle AgedPrognosisRetrospective StudiesAdultAgedClinical Trials as TopicCyclin-Dependent Kinase Inhibitor p15AstrocytomaSurvival RateFollow-Up StudiesResearch DesignYoung AdultBiomarkers, Tumor

Stichwörter der Autor:innen

CDKN2A/B homozygous deletionAstrocytomaGliomaIsocitrate dehydrogenase (IDH)WHO grade 4

Substanzen

Isocitrate DehydrogenaseCyclin-Dependent Kinase Inhibitor p16IDH1 protein, humanCDKN2A protein, humanIDH2 protein, humanCyclin-Dependent Kinase Inhibitor p15CDKN2B protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Translational Neuro-Oncology Laboratory, Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany.
  • Department of Neurosurgery, Medical Faculty, Heidelberg University, Heidelberg, Germany.
  • Pappas Center for Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
  • Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany.

Förderung

  • NINDS NIH HHS
  • NINDS

Zitieren

APA

Wetzel, E. A., Nohman, A. I., Hsieh, A. L., Reuss, D., Unterberg, A. W., Eyüpoglu, I. Y., Hua, L., Youssef, G., Wen, P. Y., Cahill, D. P., Jungk, C., Juratli, T. A., & Miller, J. J. (2025). A multi-center, clinical analysis of IDH-mutant gliomas, WHO Grade 4: implications for prognosis and clinical trial design. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-024-04852-7

Vancouver

Wetzel EA, Nohman AI, Hsieh AL, Reuss D, Unterberg AW, Eyüpoglu IY, et al. A multi-center, clinical analysis of IDH-mutant gliomas, WHO Grade 4: implications for prognosis and clinical trial design. Journal of Neuro-Oncology. 2025. doi:10.1007/s11060-024-04852-7

BibTeX
@article{Wetzel2025,
  author = {Wetzel, Ethan A and Nohman, Amin I and Hsieh, Annie L and Reuss, David and Unterberg, Andreas W and Eyüpoglu, Ilker Y and Hua, Lingyang and Youssef, Gilbert and Wen, Patrick Y and Cahill, Daniel P and Jungk, Christine and Juratli, Tareq A and Miller, Julie J},
  title = {A multi-center, clinical analysis of IDH-mutant gliomas, WHO Grade 4: implications for prognosis and clinical trial design},
  journal = {Journal of Neuro-Oncology},
  year = {2025},
  doi = {10.1007/s11060-024-04852-7}
}
Kostenlos starten →